Wall Street hates uncertainty and there are still a lot of unknowns at Wright Medical (NASDAQ:WMGI).
The full cost of the company's hip litigation has yet to be determined
and there are still outstanding questions regarding the adoption of the
Augment biologic product, competition from the likes of Stryker (NYSE:SYK),
and management's ability to successfully integrate Tornier and become a
strong extremity-focused specialty orthopedics company.
Good
performance can help ease some of those concerns, and Wright Medical's
first quarter results were good. There's still an above-average level of
skepticism regarding smaller med-tech in the market, and that keeps
Wright Medical shares priced at a discount. Given the growth prospects
for the existing product portfolio and the opportunities to leverage
further product development, these shares are worth a look from more
aggressive investors.
Follow this link for more:
Good Performance Helps Ease Some Of The Tension At Wright Medical
No comments:
Post a Comment